Nano-Curcumin Supplementation For The Management Of Migraine: A Systematic Scoping Review And Meta-Analysis

Abstract

Objectives: Migraine is a common neurological disorder contributing significantly to global disability. Nano curcumin, known for its anti-inflammatory and neuroprotective properties, has emerged as a promising candi date for migraine prophylaxis. Herein, we assessed the effects of nano-curcumin supplementation on headache attack, severity, and duration in adult patients. Methods: Five biomedical databases were searched until March 2024 for randomized controlled trials (RCTs). 13 records fulfilled the inclusion criteria, eight of which were considered for meta-analysis. The risk of bias was assessed using ROB2. Outcomes were quantified using both Standardized Mean Difference (SMD) and Mean Difference (MD) along with the 95 % Confidence Intervals (CIs). Pooled intervention effects were estimated using both common-effects and random-effects models. Results: Our analysis revealed that 80 mg nano-curcumin supplementation per day for two months in young adults reduced migraine attacks (SMD − 0.55; 95 % CI: − 1.07 to − 0.02), severity (SMD − 0.64; 95 % CI: − 1.10 to − 0.19), and duration (MD − 2.90; 95 % CI: − 4.66 to − 1.13) when compared with placebo. When combined with nutraceuticals such as omega-3 and coenzyme Q10, nano-curcumin demonstrated enhanced efficacy in reducing migraine attacks (SMD 1.19; 95 % CI: 0.90–1.48). Among those who received nano-curcumin supplementation only, a before and after intervention analysis showed a reduction in migraine attacks (SMD − 0.77; 95 % CI: − 1.00 to − 0.54), severity (SMD − 0.92; 95 % CI: − 1.50 to − 0.33), and duration (SMD − 0.63; 95 % CI: − 1.05 to − 0.20). Conclusions: Evidence from literature suggests that nano-curcumin supplementation might be effective in reducing migraine symptoms. However, caution is advised, and further research is recommended to confirm these findings, considering the single institutional source of all studies.